PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Abstract Text:

Yeon Seok Seo,Ji Hoon Kim,Nam Young Jo,Kyung Mook Choi,Sei Hyun Baik,Jong-Jae Park,Jae Seon Kim,Kwan Soo Byun,Young-Tae Bak,Chang Hong Lee,Aeree Kim,Jong Eun Yeon,Yeon Seok Seo,Ji Hoon Kim,Nam Young Jo,Kyung Mook Choi,Sei Hyun Baik,Jong-Jae Park,Jae Seon Kim,Kwan Soo Byun,Young-Tae Bak,Chang Hong Lee,AeRee Kim,Jong Eun Yeon,

Background and Aims: In a previous study, the authors found that reduced expression of peroxisome proliferator-activated receptor (PPAR)-alpha might play an important role in developing nonalcoholic fatty liver disease (NAFLD). The aim of this study was to analyze the effects of PPAR-alpha and -gamma agonists on NAFLD and verify the mechanisms underlying the PPAR-alpha and -gamma agonist-induced improvements by evaluating the hepatic gene expression profile involved in fatty-acid metabolism, using the Otsuka-Long Evans-Tokushima fatty (OLETF) rat. Methods: Rats were assigned to a control group (group I), fatty liver group (group II), PPAR-alpha agonist treatment group (group III), or PPAR-gamma agonist treatment group (group IV). Fasting blood glucose, total cholesterol, and triglycerides were measured. Liver tissues from each group were processed for histological and gene expression analysis. mRNAs of enzymes involved in fatty-acid metabolism and tumor necrosis factor (TNF)-alpha were measured. Results: After 28 weeks treatment with PPAR-alpha or -gamma agonist, steatosis of the liver was improved in groups III and IV compared with group II. Fasting blood glucose levels were significantly lower in groups III and IV than in group II. In group III, mRNA expression of fatty-acid beta-oxidation enzymes, such as fatty-acid transport protein (FATP), fatty-acid binding protein, carnitine palmitoyltransferase II, medium-chain acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase, and acyl-CoA oxidase, was significantly increased. However, the treatment-induced modulation of fatty-acid beta-oxidation enzymes was confined to FATP and MCAD in group IV. TNF-alpha tended to be reduced in groups III and IV compared with group II. Conclusions: Treatment with PPAR agonists, especially a PPAR-alpha agonist, improved the histological and biochemical parameters in the OLETF rat model by inducing fatty-acid metabolic enzymes.

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Publishing Authors By Initials

YS Seo,JH Kim,NY Jo,KM Choi,SH Baik,JJ Park,JS Kim,KS Byun,YT Bak,CH Lee,A Kim,JE Yeon,YS Seo,JH Kim,NY Jo,KM Choi,SH Baik,JJ Park,JS Kim,KS Byun,YT Bak,CH Lee,A Kim,JE Yeon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of gastroenterology and hepatology

VOLUME: 23

Page Numbers: 102-9

Journal Abbreviation: J. Gastroenterol. Hepatol.

ISSN: 0815-9319

DAY: 3

MONTH: Jan

YEAR: 2008

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8607909

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

AFFILIATION: Divisions of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, Korea.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Gastroenterol Hepatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes Related Publications

• Accuracy of electrocardiographic criteria for atrial enlargement: validation with cardiovascular magnetic resonance.
• Angiofibroma confined to the pterygoid muscle region: CT and MR demonstration.
• Central skull base lymphoma in children: MR and CT features.
• Endobronchial hamartoma: CT findings in three patients.
• Granulocytic sarcoma presenting with necrotic cervical lymph nodes as an initial manifestation of childhood leukaemia: imaging features.
• Krukenberg's tumor of the ovary: MR imaging features.
• PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
• Power Doppler imaging in acute renal vein occlusion and recanalization: a canine model.
• Radiological spectrum of hepatic mesenchymal hamartoma in children.
• Technique for the early detection of drug-resistant HBV DNA during antiviral therapy.
• [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin]